News | March 11, 2009

Screening Tests Improve Accuracy of Predicting Heart Attack Risk

March 11, 2009 – The use of common screening tests, such as the ankle brachial index (ABI), along with traditional risk scoring systems like the Framingham Risk Score, has the potential to prevent heart attacks in thousands of individuals who, based on their Framingham, are not originally thought to be at high risk, say researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting.

The ABI identifies peripheral arterial disease patients at high cardiovascular risk who were missed by Framingham Risk Score, according to the 1999-2004 National Health and Nutrition Examination Survey (NHANES) study.

In the study, information was analyzed from NHANES - a nationally representative cross-sectional survey of the U.S. population for 6,292 men and women ages 40 and older without known history of heart disease, stroke, diabetes or atherosclerotic vascular disease - along with available data on standard cardiovascular risk factors and screening tests (like the ABI, which is a comparative blood pressure test). For the first time, researchers determined the prevalence of peripheral arterial disease (PAD) in a large population of women and men who were not considered at high risk for cardiovascular disease. Moreover, novel risk factors (those not traditionally considered in the Framingham Risk Score) are abnormal in up to 45 percent of those not considered high risk for coronary heart events.

"This is significant news that can profoundly impact public health. If novel risk factors are shown to improve risk prediction, they could be very valuable because the prevalence of abnormal values is high in populations not known to have high risk," said Timothy P. Murphy, M.D., an interventional radiologist and director of the Vascular Disease Research Center at Rhode Island Hospital in Providence. "These simple tests - like ABI screening - have the potential to improve the accuracy of cardiovascular risk prediction and thereby have significant public health impact by helping identify people for intensive medical therapy and preventing heart attacks and strokes," said Dr. Murphy.

Ninety-one percent of the NHANES group was considered at low or intermediate risk of cardiovascular disease, according to Framingham criteria alone, yet almost 45 percent was found to have at least one of three conditions: an abnormal ABI or elevated plasma fibrinogen or elevated plasma C-reactive protein (CRP). "Even with abnormal ABI, which was the least prevalent of the three novel risk factors evaluated, that number translates into about 2.1 million Americans, age 40 and older, who have no known history of heart disease, stroke, diabetes or atherosclerotic vascular disease," said Dr. Murphy. "There is also a good chance that ABI, which actually detects subclinical already-established atherosclerotic disease, may actually perform better in terms of risk prediction than fibrinogen or C-reactive protein because it may be more specific," Dr. Murphy said.

"The earlier the detection of who's at risk for heart attacks is crucial. Primary prevention - such as initiating lifestyle changes and medical intervention directed at modifying risk factors (smoking cessation, blood glucose and blood pressure control, lowering cholesterol and exercise) - can be started to improve one's health before costlier and more intensive interventions are needed," said Dr. Murphy.

"Interventional radiologists often provide PAD screening tests like the ABI. Primary care doctors, who oversee medical management of the vast majority of the public at risk for cardiovascular disease, should partner with interventional radiologists in evaluating patients' risk for cardiovascular disease, as well as for managing established PAD," said Dr. Murphy.

ABI, used to diagnose PAD, is a painless test that compares the blood pressure in the legs to the blood pressure in the arms to determine how well the blood is flowing and whether further tests are needed. Elevated results for plasma fibrinogen and plasma C-reactive protein, laboratory-based tests, can indicate inflammation.

Abstract 146: "Prevalence of Low Ankle Brachial Index, Elevated Plasma Fibrinogen and CRP Among Those Otherwise at Low-Intermediate Cardiovascular Events' Risk: Data From the National Health and Nutrition Examination Survey (NHANES) 1999-2004," R. Dhangana, T.P. Murphy, M.B. Ristuccia, J.V. Cerezo and D. Tsai, all with Rhode Island Hospital/Brown University, Providence, R.I.; and M.J. Pencina, Boston University, Boston, Mass., SIR 34th Annual Scientific Meeting March 7-12, 2009. This abstract can be found at www.SIRmeeting.org.

Source: Society of Interventional Radiology
For more information: www.SIRweb.org.


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now